{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:17:55Z","timestamp":1793755075636,"version":"4.6.1"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ibrexafungerp is a novel glucan synthase inhibitor currently undergoing phase II and phase III clinical trials. This compound has demonstrated in vitro activity against clinically important fungal pathogens including Candida spp. and Aspergillus spp. It is able to retain activity against many echinocandin-resistant strains of Candida due to differential avidity for the target site compared to echinocandins. In vivo animal models have demonstrated efficacy in murine models of invasive candidiasis, aspergillosis, and pneumocystis. Due to high bioavailability, it can be administered both orally and intravenously. A favorable drug interaction and tolerability profile is observed with this compound. This review summarizes existing data that have either been published or presented at international symposia.<\/jats:p>","DOI":"10.1093\/mmy\/myz083","type":"journal-article","created":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T11:06:55Z","timestamp":1562497615000},"page":"579-592","source":"Crossref","is-referenced-by-count":93,"title":["Ibrexafungerp: A novel oral glucan synthase inhibitor"],"prefix":"10.1093","volume":"58","author":[{"given":"M R","family":"Davis","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of California, Davis Health, 2315 Stockton Blvd., Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Donnelley","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of California, Davis Health, 2315 Stockton Blvd., Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"G R","family":"Thompson","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Immunology, University of California, 1275 Med Science Dr., Davis, California, USA"},{"name":"Department of Internal Medicine, Division of Infectious Diseases, University of California, Davis Health, 4150\u00a0V Street, Suite G500, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"key":"2020063020042266500_bib1","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020063020042266500_bib2","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"2020063020042266500_bib3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ1194","article-title":"Clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020063020042266500_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020063020042266500_bib5","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020063020042266500_bib6","doi-asserted-by":"crossref","first-page":"e02068","DOI":"10.1128\/AAC.02068-16","article-title":"Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis","volume":"61","author":"Wring","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib7","doi-asserted-by":"crossref","first-page":"e00161","DOI":"10.1128\/AAC.00161-17","article-title":"Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib8","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1128\/AAC.00432-11","article-title":"Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors","volume":"55","author":"Walker","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib9","volume-title":"Morphological effect of SCY-078 and caspofungin on different caspofungin-resistant Candida species","author":"Hager","year":"2018"},{"key":"2020063020042266500_bib10","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/jac\/dkx010","article-title":"The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp","volume":"72","author":"Marcos-Zambrano","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020063020042266500_bib11","volume-title":"SCY-078 displays potent in-vitro activity against Candida glabrata isolates with mutations in fks gene","author":"Borroto-Esoda","year":"2016"},{"key":"2020063020042266500_bib12","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/AAC.02145-13","article-title":"Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates","volume":"58","author":"Jimenez-Ortigosa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib13","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/jac\/dks466","article-title":"Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)","volume":"68","author":"Pfaller","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020063020042266500_bib14","volume-title":"Activity of SCY-078 and comparators against a collection of Aspergillus spp. including cryptic species and Cyp51A mutants","author":"Rivero-Menendez","year":"2018"},{"key":"2020063020042266500_bib15","volume-title":"The first orally bioavailable, glucan synthase inhibitor, demonstrates potent in vitro activity against azole-resistant Candida spp","author":"Borroto-Esoda","year":"2016"},{"key":"2020063020042266500_bib16","doi-asserted-by":"crossref","first-page":"e02396","DOI":"10.1128\/AAC.02396-16","article-title":"The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation","volume":"61","author":"Larkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib17","doi-asserted-by":"crossref","first-page":"e00435","DOI":"10.1128\/AAC.00435-17","article-title":"In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris","volume":"61","author":"Berkow","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib18","volume-title":"Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Panel of Susceptible and Resistant Clinical Candida Isolates from Europe","author":"Borroto-Esoda","year":"2017"},{"key":"2020063020042266500_bib19","volume-title":"Susceptibility testing of SCY078 against Candida isolates obtained from a clinical study of oral SCY078 vs oral fluconazole in subjects with moderate to severe vulvovaginal candidiasis demonstrates no resistance development","author":"Borroto-Esoda","year":"2017"},{"key":"2020063020042266500_bib20","doi-asserted-by":"crossref","first-page":"e01102","DOI":"10.1128\/AAC.01102-17","article-title":"Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib21","doi-asserted-by":"crossref","first-page":"e01961","DOI":"10.1128\/AAC.01961-16","article-title":"SCY-078 is fungicidal against Candida species in time-kill studies","volume":"61","author":"Scorneaux","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib22","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020063020042266500_bib23","doi-asserted-by":"crossref","first-page":"e00833","DOI":"10.1128\/AAC.00833-17","article-title":"De novo acquisition of resistance to SCY-078 in Candida glabrata involves FKS mutations that both overlap and are distinct from those conferring echinocandin resistance","volume":"61","author":"Jimenez-Ortigosa","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib24","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01588-12","article-title":"In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods","volume":"57","author":"Pfaller","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib25","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/AAC.00234-15","article-title":"Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates","volume":"59","author":"Lamoth","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib26","doi-asserted-by":"crossref","first-page":"e00244","DOI":"10.1128\/AAC.00244-18","article-title":"Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis","volume":"62","author":"Ghannoum","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib27","volume-title":"In vitro interaction between SCY-078, echinocandins and azoles against susceptible and resistant Candida spp. determined by the checkerboard method","author":"Borroto-Esoda","year":"2017"},{"key":"2020063020042266500_bib28","volume-title":"In vitro activity of SCY-078 in combination with isavuconazole or amphotericin B against medically important moulds","author":"Petraitis","year":"2018"},{"key":"2020063020042266500_bib29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1128\/AAC.48.3.693-715.2004","article-title":"Combination antifungal therapy","volume":"48","author":"Johnson","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0169-409X(00)00128-9","article-title":"Caco-2 monolayers in experimental and theoretical predictions of drug transport","volume":"46","author":"Artursson","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"2020063020042266500_bib31","author":"Trucksis","year":"2011","journal-title":"A phase I multiple rising dose study evaluating safety, tolerability, and pharmacokinetics of MK-3118, oral glucan synthase inhibitor, in healthy volunteers"},{"key":"2020063020042266500_bib32","unstructured":"Form S-1 Registration Statement. Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/1178253\/000119312514073292\/d641160ds1.htm-toc. Accessed June 13, 2019."},{"key":"2020063020042266500_bib33","volume-title":"Penetration of SCY-078 into pulmonary epithelial lining fluid suggests potential clinical utility in pulmonary fungal infections","author":"Wring","year":"2015"},{"key":"2020063020042266500_bib34","doi-asserted-by":"crossref","first-page":"e02119","DOI":"10.1128\/AAC.02119-18","article-title":"SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [(14)C]SCY-078 in albino and pigmented rats","volume":"63","author":"Wring","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib35","volume-title":"Penetration of ibrexafungerp (formerly SCY-078) versus micafungin at the site of infection in an intra-abdominal candidiasis mouse model","author":"Lee","year":"2019"},{"key":"2020063020042266500_bib36","volume-title":"Intravenous single and multiple dose-range finding pharmacokinetics of the antifungal triterpene SCY-078 in mouse, rat and dog and comparison to efficacy target in murine models of invasive candidiasis","author":"Wring","year":"2015"},{"key":"2020063020042266500_bib37","volume-title":"A phase I single rising dose study evaluating the safety, tolerability and pharmacokinetics of an oral glucan synthase inhibitor in healthy male volunteers","author":"Trucksis","year":"2010"},{"key":"2020063020042266500_bib38","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/jcph.1146","article-title":"Lack of impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, a substrate for cyp450 2c8, supports the low risk for clinically relevant metabolic drug-drug interactions","volume":"58","author":"Wring","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"2020063020042266500_bib39","volume-title":"Effect of SCY-078 on the pharmacokinetics of a CYP2C8 substrate (rosiglitazone) results from a phase 1 clinical trial","author":"David","year":"2017"},{"key":"2020063020042266500_bib40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cpdd.588","article-title":"Clinical pharmacokinetics and drug-drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus","volume":"8","author":"Wring","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2020063020042266500_bib41","volume-title":"Pharmacokinetics and pharmacodynamics in patients from a phase 2, multicenter, open-label, randomized, comparative study of oral scy-078\u00a0vs. standard-of-care following initial intravenous echinocandin therapy in the treatment of invasive candidiasis (including candidemia) in hospitalized non-neutropenic adults","author":"Angulo","year":"2017"},{"key":"2020063020042266500_bib42","volume-title":"Lack of an effect of SCY-078 a novel antifungal agent on QTc interval in healthy subjects","author":"Murphy","year":"2017"},{"key":"2020063020042266500_bib43","volume-title":"Ibrexafungerp (formerly SCY-078), a novel IV\/oral triterpenoid antifungal treatment, is not embryo\/feto-toxic","author":"Carruthers","year":"2018"},{"key":"2020063020042266500_bib44","volume-title":"Preclinical safety evaluation of the novel antifungal ibrexafungerp (formerly SCY-078) supports long-term dosing","author":"Carruthers","year":"2019"},{"key":"2020063020042266500_bib45","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.04445-14","article-title":"Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib46","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib47","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.01430-10","article-title":"Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia","volume":"55","author":"Andes","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib48","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1128\/AAC.00095-07","article-title":"Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences","volume":"51","author":"Chamilos","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063020042266500_bib49","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jac\/dkx422","article-title":"Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020063020042266500_bib50","volume-title":"Efficacy of oral ibrexafungerp (formerly SCY-078) in the treatment of Candida auris infection in a murine model","author":"Ghannoum","year":"2019"},{"key":"2020063020042266500_bib51","volume-title":"Evaluation of enfumafungin derivative MK-3118 in two mouse models of disseminated aspergillosis","author":"Flattery","year":"2010"},{"key":"2020063020042266500_bib52","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx163.1207","volume-title":"SCY-078 demonstrates significant antifungal activity in a murine model of invasive aspergillosis","author":"Borroto-Esoda K","year":"2017"},{"key":"2020063020042266500_bib53","volume-title":"SCY-078 demonstrates antifungal activity against pneumocystis in a prophylactic murine model of Pneumocystis pneumonia","author":"Ashbaugh","year":"2018"},{"key":"2020063020042266500_bib54","volume-title":"Efficacy of ibrexafungerp (formerly SCY-078) against Pneumocystis pneumonia in a murine therapeutic model","author":"Barat","year":"2019"},{"key":"2020063020042266500_bib55","volume-title":"SCY-078 phase 2 study in moderate and severe vulvovaginal candidiasis","author":"Roman","year":"2017"},{"key":"2020063020042266500_bib56","volume-title":"Interim analysis of a phase 3 open-label study to evaluate the efficacy and safety of oral ibrexafungerp (formerly SCY-078) in patients with refractory or intolerant fungal diseases (FURI)","author":"Cornely","year":"2019"},{"key":"2020063020042266500_bib57","volume-title":"Successful treatment of two patients with Candida auris candidemia with the investigational agent, oral ibrexafungerp (formerly SCY-078), from the CARES Study","author":"Juneja","year":"2019"},{"key":"2020063020042266500_bib58","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01510-19","volume-title":"Activity of a novel 1,3-beta-D-glucan inhibitor, ibrexafungerp (formerly SCY-078), against Candida glabrata","author":"Ghannoum","year":"2019"},{"key":"2020063020042266500_bib59","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1086\/504492","article-title":"Pharmacology of systemic antifungal agents","volume":"43","author":"Ashley","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020063020042266500_bib60","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1345\/aph.1M237","article-title":"Echinocandins: the newest class of antifungals","volume":"43","author":"Sucher","year":"2009","journal-title":"Ann Pharmacother"},{"key":"2020063020042266500_bib61","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1128\/AAC.48.3.815-823.2004","article-title":"Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma","volume":"48","author":"Stone","year":"2004","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/58\/5\/579\/33431557\/myz083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/58\/5\/579\/33431557\/myz083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T02:49:40Z","timestamp":1663901380000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/58\/5\/579\/5538259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,7,25]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myz083","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2019,7,25]]}}}